ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

ALZN Alzamend Neuro Inc

0.726
-0.009 (-1.22%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Alzamend Neuro Inc ALZN NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.009 -1.22% 0.726 16:28:45
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.735 0.7152 0.74 0.726 0.735
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
07/3/202415:30EDGAR2Form 8-K - Current report
02/2/202415:30EDGAR2Form 8-K - Current report
05/1/202415:30EDGAR2Form 8-K - Current report
15/12/202315:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/12/202307:00BWAlzamend Neuro Receives FDA “Study May Proceed” Notification..
20/11/202307:00BWAlzamend Neuro Receives FDA “Study May Proceed” Notification..
16/11/202315:30EDGAR2Form 8-K - Current report
16/11/202307:00BWAlzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid..
13/11/202307:00BWAlzamend Neuro Submits IND Application for a Phase IIA..
30/10/202315:30EDGAR2Form 8-K - Current report
30/10/202307:00BWAlzamend Neuro Announces Reverse Stock Split
23/10/202307:00BWAlzamend Neuro Submits IND Application for a Phase IIA..
02/10/202307:00BWAlzamend Neuro Receives FDA “Study May Proceed” Notification..
29/9/202315:30EDGAR2Form 8-K - Current report
26/9/202317:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/9/202315:30EDGAR2Form 8-K - Current report
22/9/202307:00BWAlzamend Neuro Granted Extension by Nasdaq Panel to Regain..
13/9/202316:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/9/202316:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08/9/202316:00EDGAR2Form 8-K - Current report
01/9/202315:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
30/8/202307:00BWAlzamend Neuro Submits IND Application for Phase IIA..
24/8/202315:30EDGAR2Form DEF 14A - Other definitive proxy statements
16/8/202315:30EDGAR2Form 8-K - Current report
10/8/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
10/8/202315:30EDGAR2Form PRE 14A - Other preliminary proxy statements
07/8/202315:30EDGAR2Form 8-K - Current report
02/8/202315:31EDGAR2Form S-3 - Registration statement under Securities Act of..
27/7/202315:56EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
22/6/202307:00BWAlzamend Neuro Announces Positive Phase IIA Clinical Trial..
13/6/202307:00BWAlzamend Neuro CEO Stephan Jackman to Participate on the..

Su Consulta Reciente

Delayed Upgrade Clock